Metabolic Abnormalities in Alzheimer Disease

DOI: 10.1007/978-0-387-79112-8_22 In book: Metabolic Encephalopathy, pp.483-530


In 1906, German neuropathologist and psychiatrist Alois Alzheimer described “eine eigenartige Erkrankung der Hirnrinde” (a
peculiar disease of the cerebral cortex). Alzheimer noted two abnormalities in autopsied brain tissue from his index case:
senile plaques, proteinaceous structures previously described in the brain of normal elderly people; and abnormal cells delineated
with silver stain that became known as neurofibrillary tangles (NFTs). The distribution and abundance of tangle-filled neurons
are now the main criteria used to diagnose Alzheimer disease (AD) at autopsy.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: The concept of excitotoxicity, neuronal death produced by overstimulation of excitatory amino acid receptors, has become a popular way of explaining the pathogenesis of neuronal death in a variety of acute and chronic neurologic diseases. While there is strong evidence supporting the role of excitotoxicity in acute processes such as hypoxia/ischemia and hypoglycemia, the role of excitotoxicity in chronic neurologic disease is not firmly established. To account for the inter- and intraregional variations in pathology of different neurodegenerative disorders, we suggest two modified forms of the excitotoxic hypothesis in which specific populations of neurons become more vulnerable to excitotoxic insult either by (1) possessing abnormal excitatory amino acid receptor subtypes or (2) being afflicted by any disease process that impairs cellular energy metabolism or otherwise decreases neuronal membrane potential. In these ways, excitotoxicity may be a final common pathway of neuronal death in a variety of neurodegenerative diseases.
    Neurology 05/1992; 42(4):733-8. DOI:10.1212/WNL.42.4.733 · 8.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Presenilins (PSs) are part of the gamma-secretase complex that produces the amyloid beta-peptide (Abeta) from its precursor [beta-amyloid precursor protein (betaAPP)]. Mutations in PS that cause familial Alzheimer's disease (FAD) increase Abeta production and trigger p53-dependent cell death. We demonstrate that PS deficiency, catalytically inactive PS mutants, gamma-secretase inhibitors, and betaAPP or amyloid precursor protein-like protein 2 (APLP2) depletion all reduce the expression and activity of p53 and lower the transactivation of its promoter and mRNA expression. p53 expression also is diminished in the brains of PS- or betaAPP-deficient mice. The gamma- and epsilon-secretase-derived amyloid intracellular C-terminal domain (AICD) fragments (AICDC59 and AICDC50, respectively) of betaAPP trigger p53-dependent cell death and increase p53 activity and mRNA. Finally, PS1 mutations enhance p53 activity in human embryonic kidney 293 cells and p53 expression in FAD-affected brains. Thus our study shows that AICDs control p53 at a transcriptional level, in vitro and in vivo, and that FAD mutations increase p53 expression and activity in cells and human brains.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 07/2006; 26(23):6377-85. DOI:10.1523/JNEUROSCI.0651-06.2006 · 6.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The microtubule-associated protein, tau, is the principal component of paired helical filaments (PHFs) in Alzheimer's disease. PHF-tau is highly phosphorylated and a total of 25 sites of phosphorylation have so far been identified. Many of these sites are serine or threonine residues that are immediately followed in the sequence by proline residues, and hence are candidate phosphorylation sites for proline-directed kinases. In vitro, glycogen synthase kinase-3 (GSK-3), extracellular signal-related kinase-1 and -2, and mitogen-activated protein kinases, p38 kinase and c-jun N-terminal kinase, all phosphorylate many of these sites, although with different efficiencies for particular sites. Phosphorylation studies in transfected cells and neurons show that GSK-3 phosphorylates tau more extensively than do these other proline-directed kinases. Mutations in tau have been shown to affect in vitro phosphorylation of tau by GSK-3. The Arg406-->Trp (R406W) tau mutation also affects tau phosphorylation in cells.
    Biochemical Society Symposium 02/2001; 67(67):73-80. DOI:10.1042/bss0670073 · 3.38 Impact Factor
Show more

Florian Gebhardt